BIOMARKERS MARKET ANALYSIS

Biomarkers Market, By Product Type (Biomarkers Test Kits, Biomarker Analyzer), By Application (Diagnostic Biomarkers, Monitoring Biomarkers, Drug discovery and development, Predictive biomarkers, Prognostic biomarkers), By Disease Indication (Cancer, Cardiovascular disorders, Neurological Disorder, Infectious Disease, Others (Immunological Disorder, and Autoimmune Disorders among others )), By End User (Hospitals, Research laboratories, Diagnostic laboratories, Research and academic institute), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Jan 2023
Code : CMI1530
Pages :187
Formats :
Excel and PDF
Industry : Biotechnology

Biomarkers MarketSize and Trends

The Global biomarkers market is estimated to be valued at US$ 55.59 Bn in 2022 and is expected to exhibit a CAGR of 13.6% over the forecast period (2022-2030).

Increase in the numbers of research and development initiatives for improving the effectiveness of biomarkers based tests and assays is expected to boost the growth of global biomarker market over the forecast period. For instance, on March 29, 2021, FUJIFILM Wako Pure Chemical Corporation is a manufacturer of laboratory chemicals and automated laboratory solutions, announced the launch of “N501Y mutation detection kit” and “E484K mutation detection kit”. This kits are developed to detect the SARS-CoV-2 mutations.

Increase in the inorganic growth activity such as collaborations among market players is expected to drive the market growth over the forecast period. For instance, in June 2022, Nordic Bioscience and Roche Diagnostics has announced collaboration for development of biomarkers for chronic diseases. Nordic bioscience is a global player in providing biomarkers for lethal and major disease indications for pipeline required during pre-clinical and clinical development. Roche diagnostics India is a division of Roche, providing diagnostic solutions. Under this collaboration, Nordic Bioscience will transfer unique and proprietary blood-based biomarkers to Roche Diagnostics to be implemented on the automated COBAS platform. Nordic bioscience’s extracellular matrix proteins (ECM) biomarkers are used for diagnosis of all chronic diseases.